NASDAQ:ASMB - Assembly Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$22.49 -0.39 (-1.70 %)
(As of 02/20/2019 03:02 AM ET)
Previous Close$22.88
Today's Range$21.74 - $23.46
52-Week Range$18.58 - $67.36
Volume145,000 shs
Average Volume200,852 shs
Market Capitalization$572.66 million
P/E Ratio-9.34
Dividend YieldN/A
Beta1.37
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.

Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ASMB
CUSIP92282210
Phone317-210-9311

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.02 million
Book Value$5.62 per share

Profitability

Net Income$-42,800,000.00
Net Margins-469.91%

Miscellaneous

Employees92
Market Cap$572.66 million
OptionableOptionable

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences Inc (NASDAQ:ASMB) released its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.01) by $0.14. The biopharmaceutical company earned $4.29 million during the quarter, compared to analysts' expectations of $3.21 million. Assembly Biosciences had a negative return on equity of 50.63% and a negative net margin of 469.91%. View Assembly Biosciences' Earnings History.

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Assembly Biosciences.

What price target have analysts set for ASMB?

5 brokerages have issued twelve-month target prices for Assembly Biosciences' stock. Their forecasts range from $42.00 to $75.00. On average, they expect Assembly Biosciences' stock price to reach $57.20 in the next twelve months. This suggests a possible upside of 154.3% from the stock's current price. View Analyst Price Targets for Assembly Biosciences.

What is the consensus analysts' recommendation for Assembly Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences.

Has Assembly Biosciences been receiving favorable news coverage?

News stories about ASMB stock have trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Assembly Biosciences earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,346,142 shares, an increase of 42.0% from the January 15th total of 947,884 shares. Based on an average trading volume of 120,035 shares, the short-interest ratio is presently 11.2 days. Currently, 6.0% of the shares of the stock are short sold. View Assembly Biosciences' Current Options Chain.

Who are some of Assembly Biosciences' key competitors?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the folowing people:
  • Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 43)
  • Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 47)
  • Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 69)
  • Mr. Thomas E. Rollins, Exec. Officer (Age 63)
  • Mr. David J. Barrett CPA, Consultant (Age 43)

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (9.72%), BlackRock Inc. (7.50%), venBio Select Advisor LLC (3.93%), Orbimed Advisors LLC (3.91%), RTW Investments LP (2.70%) and Victory Capital Management Inc. (2.09%). Company insiders that own Assembly Biosciences stock include Derek A Small, Uri A Lopatin and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences.

Which institutional investors are selling Assembly Biosciences stock?

ASMB stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, venBio Select Advisor LLC, Emerald Advisers LLC, Northern Trust Corp, MetLife Investment Advisors LLC, National Asset Management Inc., California Public Employees Retirement System and Barclays PLC. Company insiders that have sold Assembly Biosciences company stock in the last year include Uri A Lopatin and William R Ringo. View Insider Buying and Selling for Assembly Biosciences.

Which institutional investors are buying Assembly Biosciences stock?

ASMB stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Sectoral Asset Management Inc, Prosight Management LP, 361 Capital LLC, BlackRock Inc., Fosun International Ltd, Dimensional Fund Advisors LP and Squarepoint Ops LLC. View Insider Buying and Selling for Assembly Biosciences.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $22.49.

How big of a company is Assembly Biosciences?

Assembly Biosciences has a market capitalization of $572.66 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 92 workers across the globe.

What is Assembly Biosciences' official website?

The official website for Assembly Biosciences is http://www.assemblybio.com.

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]


MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel